A Comprehensive Review of Ovarian Serous Carcinoma

Although ovarian serous carcinoma is a well-studied human gynecologic malignancy, this high-grade tumor remains fatal. The main purpose of this review is to summarize the accumulated evidence on serous malignant tumors and to clarify the unresolved issues. We discuss the 8 dichotomies of serous carcinoma: high grade versus low grade, ovarian versus extraovarian primary, extrauterine versus uterine primary, sporadic versus hereditary, orthodox versus alternative histology, p53 overexpression versus complete absence of immunophenotype, TP53-mutated versus intact precursor, and therapy responsive versus refractory. In addition, we summarize the molecular classification of high-grade serous carcinoma. This review would lead readers to rapid and parallel developments in understanding high-grade serous carcinoma.

• Publication year

  2019

• Venue

  Advances in Anatomic Pathology

• Publication date

  2019-07-26

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/PAP.0000000000000243PMID 31368906PMCID 7043727
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• High-grade serous ovarian carcinoma with mucinous differentiation: report of a rare and unique case suggesting transition from the “SET” feature of high-grade serous carcinoma to the “STEM” feature

  2019cited by this paper
• Tubo-Ovarian Transitional Cell Carcinoma and High-grade Serous Carcinoma Show Subtly Different Immunohistochemistry Profiles

  2019cited by this paper
• Uncommon hereditary gynaecological tumour syndromes: pathological features in tumours that may predict risk for a germline mutation.

  2018cited by this paper
• Evidence for lineage continuity between early serous proliferations (ESPs) in the Fallopian tube and disseminated high‐grade serous carcinomas

  2018cited by this paper
• High grade serous intraepithelial carcinoma arising in a benign ovarian serous cyst - a bridge too far?

  2018cited by this paper
• International Endocervical Adenocarcinoma Criteria and Classification (IECC): A New Pathogenetic Classification for Invasive Adenocarcinomas of the Endocervix

  2018cited by this paper
• High-grade serous carcinoma with discordant p53 signature: report of a case with new insight regarding high-grade serous carcinogenesis

  2018cited by this paper
• The Wilms' tumour 1 gene as a factor in non-syndromic hypospadias: evidence and controversy.

  2018cited by this paper
• Serous tubal intraepithelial neoplasia: the concept and its application

  2017cited by this paper
• Uterine Serous Carcinomas Frequently Metastasize to the Fallopian Tube and Can Mimic Serous Tubal Intraepithelial Carcinoma

  2017cited by this paper
• Uterine Carcinosarcomas: Clinical, Histopathologic and Immunohistochemical Characteristics

  2017cited by this paper
• Pooled Clustering of High-Grade Serous Ovarian Cancer Gene Expression Leads to Novel Consensus Subtypes Associated with Survival and Surgical Outcomes

  2017cited by this paper
• Prognostic indicators in ovarian serous borderline tumours.

  2017cited by this paper
• High‐grade serous carcinoma of tubo‐ovarian origin: recent developments

  2017cited by this paper
• Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers

  2017cited by this paper
• Gynaecological neoplasms in common familial syndromes (Lynch and HBOC).

  2017cited by this paper
• The Fallopian Tube Origin and Primary Site Assignment in Extrauterine High-grade Serous Carcinoma: Findings of a Survey of Pathologists and Clinicians

  2017cited by this paper
• Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial.

  2017cited by this paper
• Counselling framework for moderate-penetrance cancer-susceptibility mutations

  2016cited by this paper
• Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study

  2016cited by this paper
• The Dualistic Model of Ovarian Carcinogenesis: Revisited, Revised, and Expanded.

  2016cited by this paper
• Adopting a Uniform Approach to Site Assignment in Tubo-Ovarian High-Grade Serous Carcinoma: The Time has Come.

  2016cited by this paper
• An Immunohistochemical Algorithm for Ovarian Carcinoma Typing

  2016cited by this paper
• Cyclin E as a potential therapeutic target in high grade serous ovarian cancer.

  2016cited by this paper
• Hereditary breast and ovarian cancer: new genes in confined pathways

  2016cited by this paper
• Kirsten Ras* oncogene: Significance of its discovery in human cancer research

  2016cited by this paper
• Establishment of a Novel Histopathological Classification of High-Grade Serous Ovarian Carcinoma Correlated with Prognostically Distinct Gene Expression Subtypes.

  2016cited by this paper
• BRCA somatic mutations and epigenetic BRCA modifications in serous ovarian cancer.

  2016cited by this paper
• Immunohistochemical Profiling of Endometrial Serous Carcinoma

  2016cited by this paper
• Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li‐Fraumeni syndrome cohort

  2016cited by this paper
• CCNE1 Amplification and Centrosome Number Abnormality in Serous Tubal Intraepithelial Carcinoma- Further Evidence Supporting its Role as a Precursor of Ovarian High-Grade Serous Carcinoma

  2016cited by this paper
• Ovarian Cancer Risk Factors by Histologic Subtype: An Analysis From the Ovarian Cancer Cohort Consortium.

  2016cited by this paper
• Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer.

  2016cited by this paper
• Optimized p53 immunohistochemistry is an accurate predictor of TP53 mutation in ovarian carcinoma

  2016cited by this paper
• Primary sources of pelvic serous cancer in patients with endometrial intraepithelial carcinoma

  2015cited by this paper
• Chemotherapy Response Score: Development and Validation of a System to Quantify Histopathologic Response to Neoadjuvant Chemotherapy in Tubo-Ovarian High-Grade Serous Carcinoma.

  2015cited by this paper
• Whole–genome characterization of chemoresistant ovarian cancer

  2015cited by this paper
• Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer.

  2015cited by this paper
• Revisiting Li-Fraumeni Syndrome From TP53 Mutation Carriers.

  2015cited by this paper
• Evidence for a Dualistic Model of High-grade Serous Carcinoma: BRCA Mutation Status, Histology, and Tubal Intraepithelial Carcinoma

  2015cited by this paper
• Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population.

  2015cited by this paper
• WHO classification of tumours of female reproductive organs

  2014cited by this paper
• Prognostic and therapeutic relevance of molecular subtypes in high-grade serous ovarian cancer.

  2014cited by this paper
• Targeting RAS–ERK signalling in cancer: promises and challenges

  2014cited by this paper
• Staging classification for cancer of the ovary, fallopian tube, and peritoneum

  2014cited by this paper
• 2014 FIGO staging for ovarian, fallopian tube and peritoneal cancer.

  2014cited by this paper
• Ovarian Transitional Cell Carcinoma Represents a Poorly Differentiated Form of High-grade Serous or Endometrioid Adenocarcinoma

  2013cited by this paper
• Signatures of mutational processes in human cancer

  2013cited by this paper
• The use of CT findings to predict extent of tumor at primary surgery for ovarian cancer.

  2013cited by this paper
• Reclassification of serous ovarian carcinoma by a 2‐tier system

  2012cited by this paper
• Low‐grade serous carcinomas of the ovary contain very few point mutations

  2012cited by this paper
• Validation of an Algorithm for the Diagnosis of Serous Tubal Intraepithelial Carcinoma

  2012cited by this paper
• Morphologic patterns associated with BRCA1 and BRCA2 genotype in ovarian carcinoma

  2012cited by this paper
• Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer.

  2012cited by this paper
• Reclassification of Serous Ovarian Carcinoma by a 2-Tier System: A Gynecologic Oncology Group Study

  2012cited by this paper
• TP53 mutations in serous tubal intraepithelial carcinoma and concurrent pelvic high‐grade serous carcinoma—evidence supporting the clonal relationship of the two lesions

  2012cited by this paper
• Prognostically relevant gene signatures of high-grade serous ovarian carcinoma.

  2012cited by this paper
• Integrated Genomic Analyses of Ovarian Carcinoma

  2011cited by this paper
• Deregulation of MYCN, LIN28B and LET7 in a Molecular Subtype of Aggressive High-Grade Serous Ovarian Cancers

  2011cited by this paper
• Secondary somatic mutations restoring BRCA1/2 predict chemotherapy resistance in hereditary ovarian carcinomas.

  2011cited by this paper
• Are All Pelvic (Nonuterine) Serous Carcinomas of Tubal Origin?

  2010cited by this paper
• Oestrogen‐induced epithelial–mesenchymal transition of endometrial epithelial cells contributes to the development of adenomyosis

  2010cited by this paper
• HMGA2: A biomarker significantly overexpressed in high-grade ovarian serous carcinoma

  2010cited by this paper
• Driver mutations in TP53 are ubiquitous in high grade serous carcinoma of the ovary

  2010cited by this paper
• Germline mutations in breast and ovarian cancer pedigrees establish RAD51C as a human cancer susceptibility gene

  2010cited by this paper
• High-grade fimbrial-ovarian carcinomas are unified by altered p53, PTEN and PAX2 expression

  2010cited by this paper
• Secretory cell outgrowth, PAX2 and serous carcinogenesis in the Fallopian tube

  2010cited by this paper
• Shortened Telomeres in Serous Tubal Intraepithelial Carcinoma: An Early Event in Ovarian High-grade Serous Carcinogenesis

  2010cited by this paper
• Integrated Genome-Wide DNA Copy Number and Expression Analysis Identifies Distinct Mechanisms of Primary Chemoresistance in Ovarian Carcinomas

  2009cited by this paper
• Transitional Cell Tumors of the Ovary: A Comparative Clinicopathologic, Immunohistochemical, and Molecular Genetic Analysis of Brenner Tumors and Transitional Cell Carcinomas

  2009cited by this paper
• Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss

  2009cited by this paper
• The first 30 years of p53: growing ever more complex

  2009cited by this paper
• Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers

  2008cited by this paper
• HMGA2 gene is a promising target for ovarian cancer silencing therapy

  2008cited by this paper
• Resistance to therapy caused by intragenic deletion in BRCA2

  2008cited by this paper
• Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome

  2008cited by this paper
• Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance.

  2008cited by this paper
• Ten genes for inherited breast cancer.

  2007cited by this paper
• A candidate precursor to serous carcinoma that originates in the distal fallopian tube

  2007cited by this paper
• Risk-reducing salpingo-oophorectomy in patients with germline mutations in BRCA1 or BRCA2.

  2007cited by this paper
• A candidate precursor to serous carcinoma that originates in the distal fallopian tube (J Pathol 2007; 211: 26–35)

  2007cited by this paper
• Intraepithelial Carcinoma of the Fimbria and Pelvic Serous Carcinoma: Evidence for a Causal Relationship

  2007cited by this paper
• Analysis of gene amplification and prognostic markers in ovarian cancer using comparative genomic hybridization for microarrays and immunohistochemical analysis for tissue microarrays.

  2006cited by this paper
• Genetic/familial high-risk assessment: breast and ovarian.

  2006cited by this paper
• The Tubal Fimbria Is a Preferred Site for Early Adenocarcinoma in Women With Familial Ovarian Cancer Syndrome

  2006cited by this paper
• Minimal uterine serous carcinoma: a clinicopathological study of 40 cases

  2005cited by this paper
• World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of the Breast and Female Genital Organs

  2005cited by this paper
• Patterns of Gene Expression in Different Histotypes of Epithelial Ovarian Cancer Correlate with Those in Normal Fallopian Tube, Endometrium, and Colon

  2005cited by this paper
• Hereditary cancer predisposition syndromes.

  2005cited by this paper
• Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy.

  2005cited by this paper
• WT1 is of value in ascertaining the site of origin of serous carcinomas within the female genital tract.

  2004cited by this paper
• Gene expression signature with independent prognostic significance in epithelial ovarian cancer.

  2004cited by this paper
• Hallmarks of 'BRCAness' in sporadic cancers

  2004cited by this paper
• BRCA1 and BRCA2: 1994 and beyond

  2004cited by this paper
• Grading Ovarian Serous Carcinoma Using a Two-Tier System

  2004cited by this paper
• The variant E233G of the RAD51D gene could be a low‐penetrance allele in high‐risk breast cancer families without BRCA1/2 mutations

  2004cited by this paper
• Ovarian tumorigenesis: a proposed model based on morphological and molecular genetic analysis.

  2004cited by this paper
• Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer.

  2003cited by this paper
• Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma.

  2003cited by this paper
• Cyclin E expression is a significant predictor of survival in advanced, suboptimally debulked ovarian epithelial cancers: a Gynecologic Oncology Group study.

  2003cited by this paper

• P53 Puzzle: WWP1 and PARC Immunohistochemistry Illuminate New Pathways for Serous Ovarian Cancer.

  2025cites this paper
• A Decade of Ovarian Cancer in Indonesia: Epidemiology and Survival Analysis from 2010 to 2020

  2025cites this paper
• Decoding β-catenin expression patterns in ovarian serous carcinoma with clinicopathological implications: insights from National Cancer Institute

  2024cites this paper
• Comparative Histopathological Analysis of Ovarian Tumors with an Emphasis on High-Grade Serous Carcinoma Prevalence

  2024cites this paper
• [18F]Fluorthanatrace PET in Ovarian Cancer: Comparison with [18F]FDG PET, Lesion Location, Tumor Grade, and Breast Cancer Gene Mutation Status

  2024cites this paper
• Comprehensive Analysis of DNA Methyltransferases Expression in Primary and Relapsed Ovarian Carcinoma

  2023cites this paper
• Comprehensive Review of Serous Tumors of Tubo-Ovarian Origin: Clinical Behavior, Pathological Correlation, Current Molecular Updates, and Imaging Manifestations.

  2023cites this paper
• Artificial intelligence-enabled microbiome-based diagnosis models for a broad spectrum of cancer types

  2023cites this paper
• Targeting ovarian cancer stem cells: a new way out

  2023influential citation
• Dynamic contrast-enhanced magnetic resonance imaging in epithelial ovarian tumor categorization: comparison with apparent diffusion coefficient histogram analysis and the tumor cell proliferation marker.

  2023cites this paper
• Evaluation of Preoperative Serum CA-125 as a Predictor of Cancer Severity

  2023cites this paper
• Advances in nanotechnology-enabled drug delivery for combining PARP inhibitors and immunotherapy in advanced ovarian cancer

  2023influential citation
• Trace Elements as a Specific Marker for Ovarian Cancer Biomineralization

  2023cites this paper
• The Pathology according to p53 Pathway

  2023cites this paper
• Histopathological Evaluation and Molecular Diagnostic Tests for Peritoneal Metastases with Unknown Primary Site—a Review

  2022cites this paper
• Usnic acid-induced programmed cell death in ovarian cancer cells

  2022cites this paper
• The Evolution of Ovarian Carcinoma Subclassification

  2022influential citation
• Primary high grade serous carcinoma of the appendix: a diagnostic dilemma.

  2022cites this paper
• The Many Faces of Serous Neoplasms and Related Lesions of the Female Pelvis: A Review

  2022cites this paper
• Next Generation Sequencing and Molecular Biomarkers in Ovarian Cancer—An Opportunity for Targeted Therapy

  2022influential citation
• Axillary lymph‐node metastases as the primary presentation of high‐grade serous ovarian carcinoma: A case report

  2022cites this paper
• Iatrogenic Leptomeningeal Carcinomatosis Following Craniotomy for Resection of Metastatic Serous Ovarian Carcinoma: A Systematic Literature Review and Case Report

  2022cites this paper
• Histogram analysis of apparent diffusion coefficient on diffusion weighted magnetic resonance imaging in differentiation between low and high grade serous ovarian cancer.

  2022cites this paper
• Promising Therapeutic Impact of a Selective Estrogen Receptor Downregulator, Fulvestrant, as Demonstrated In Vitro upon Low-Grade Serous Ovarian Carcinoma Cell Lines

  2022cites this paper
• LncRNA LIFR‐AS1 overexpression suppressed the progression of serous ovarian carcinoma

  2022cites this paper
• Evaluation of the prognostic value of lymphadenectomy for low-grade serous ovarian cancer: A case-control multicenter retrospective study

  2022cites this paper
• Role of Neoadjuvant Chemotherapy in Ovarian Serous Cancer Followed by Debulking

  2022cites this paper
• Role of RAS signaling in ovarian cancer

  2022cites this paper
• The Study of the Nanocrystalline Structure of Psammoma Bodies of Serous Ovarian Carcinoma

  2022cites this paper
• Pathological Features of Ovarian Tumors, Diagnosed at a Tertiary Care Hospital in Afghanistan: A Cross-sectional Study

  2022cites this paper
• Shifting incidence and survival of epithelial ovarian cancer (1995‐2014): A SurvMark‐2 study

  2022cites this paper
• Low-Grade Ovarian Serous Adenocarcinoma with Lymph Node Metastasis in Neck

  2021cites this paper
• Detection of Serous Tubal Intraepithelial Carcinoma along with High Grade Serous Carcinoma of Both Ovaries.

  2021cites this paper
• Virus-Driven Carcinogenesis

  2021cites this paper
• Novel clinical and morphological predictors of malignancy in patients with ovarian endometrioid cysts

  2021cites this paper
• H2O2-Driven Anticancer Activity of Mn Porphyrins and the Underlying Molecular Pathways

  2021cites this paper
• Detection of Tumor-Specific PTPmu in Gynecological Cancer and Patient Derived Xenografts

  2021cites this paper
• CD133 Act as an Essential Marker in Ovarian Carcinogenesis

  2021cites this paper
• Progesterone Receptor Membrane Component (PGRMC)1 and PGRMC2 and Their Roles in Ovarian and Endometrial Cancer

  2021cites this paper
• Treatment of Carcinosarcoma of the Fallopian Tube Mimicking Ovarian Cancer: A Case Report and Genetic Analysis.

  2021cites this paper
• Potential Role of Hydroxyapatite Nanocrystalline for Early Diagnostics of Ovarian Cancer

  2021cites this paper
• Hereditary Breast and Ovarian Cancer: Current Concepts of Prevention and Treatment

  2021influential citation
• Metastatic colon cancer of the small intestine diagnosed using genetic analysis: a case report

  2020cites this paper
• [Ovarian carcinomas histoseminar. Case 2].

  2020cites this paper
• Pathology of Peritoneal Metastases: The Unchartered Fields

  2020cites this paper
• Molecular Trajectory of BRCA1 and BRCA2 Mutations

  2020influential citation
• [Ovarian carcinomas histoseminar. Case 1].

  2020cites this paper
• A tunnel approach in laparoscopically assisted radical right hemicolectomy – a video vignette

  2020cites this paper
• Approach to a Patient with Peritoneal Metastases with Unknown Primary Site: Focus on Histopathological Evaluation

  2020cites this paper
• Importance of serous intraepithelial ovarian tubal carcinomas in the occurrence of "high-grade" serous carcinomas and / or peritoneal serous carcinomas of unknown primary origin.

  2020cites this paper
• Bleeding and bowel obstruction in giant ovarian serous carcinoma – a video vignette

  2020cites this paper